Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2001 Jul;85(7):842–847. doi: 10.1136/bjo.85.7.842

Bacterial keratitis: a prospective clinical and microbiological study

F Schaefer 1, O Bruttin 1, L Zografos 1, Y Guex-Crosier 1
PMCID: PMC1724042  PMID: 11423460

Abstract

AIM—To define the clinical and microbiological profile of bacterial keratitis at the Jules Gonin Eye Hospital and to test the in vitro bacterial resistance.
METHODS—Patients presenting with bacterial keratitis were prospectively followed; clinical features (age, risk factors, visual acuity) and response to therapy were analysed. Bacteriological profile was determined and the sensitivity/resistance of isolated strains were tested towards 12 ocular antibiotics (NCCLS disc diffusion test).
RESULTS—85 consecutive patients (mean age 44.3 (SD 20.7) years) were prospectively enrolled from 1 March 1997 to 30 November 1998. The following risk factors were identified: contact lens wear, 36%; blepharitis, 21%; trauma, 20%; xerophthalmia, 15%; keratopathies, 8%; and eyelid abnormalities, 6%. The most commonly isolated bacteria were Staphylococcus epidermidis, 40%; Staphylococcus aureus, 22%; Streptococcus pneumoniae, 8%; others Streptococcus species, 5%; Pseudomonas, 9%; Moraxella and Serratia marcescens, 5% each; Bacillus, Corynebacterium, Alcaligenes xyloxidans, Morganella morganii, and Haemophilus influenza, 1% each. 1-15% of strains were resistant to fluoroquinolones, 13-22% to aminoglycosides, 37% to cefazolin, 18% to chloramphenicol, 54% to polymyxin B, 51% to fusidic acid, and 45% to bacitracin. Five of the 85 patients (5.8%) had a poor clinical outcome with a visual loss of one or more lines of visual acuity.
CONCLUSION—Fluoroquinolones appear to be the therapy of choice for bacterial keratitis, but, based upon these in vitro studies, some strains may be resistant.



Full Text

The Full Text of this article is available as a PDF (153.1 KB).

Figure 1  .

Figure 1  

Open in a new tab

Contact lens wear is by far the most common risk factor encountered. The numbers refer to the numbers of patients. Blepharitis and trauma are also major risk factors for the development of keratitis. Other aetiologies, such as dry eye syndrome, keratopathies, and eyelid pathologies, are less common risk factors.

Figure 2  .

Figure 2  

Open in a new tab

Gram positive bacteria are by far the most commonly isolated organisms of which Staphylococcus species predominate. Pseudomonas aeruginosa is the Gram negative bacterium most encountered.

Figure 3  .

Figure 3  

Figure 3  

Open in a new tab

Chloramphenicol, cefazolin, and new fluoroquinolones (particularly ofloxacin) are very effective against Gram positive bacteria. In contrast, many of these same bacteria are resistant to polymyxin B (A). Similar to the effectiveness against Gram positive bacteria, the new fluoroquinolones are also effective against Gram negative bacteria. Aminoglycosides (tobramycin, neomycin, and gentamicin) also provide a broad spectrum of activity against Gram negative pathogens. Bacitracin, cefazolin, chloramphenicol, and fusidic acid, on the contrary, have little effect against these bacteria (B).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan B. D., Dart J. K. Strategies for the management of microbial keratitis. Br J Ophthalmol. 1995 Aug;79(8):777–786. doi: 10.1136/bjo.79.8.777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chaudhuri P. R., Godfrey B. Treatment of bacterial corneal ulcers with concentrated antibiotic eye drops. Trans Ophthalmol Soc U K. 1982 Apr;102(Pt 1):11–14. [PubMed] [Google Scholar]
  3. Cruz C. S., Cohen E. J., Rapuano C. J., Laibson P. R. Microbial keratitis resulting in loss of the eye. Ophthalmic Surg Lasers. 1998 Oct;29(10):803–807. [PubMed] [Google Scholar]
  4. Cutarelli P. E., Lass J. H., Lazarus H. M., Putman S. C., Jacobs M. R. Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. Curr Eye Res. 1991 Jun;10(6):557–563. doi: 10.3109/02713689109001764. [DOI] [PubMed] [Google Scholar]
  5. Diamond J., Leeming J., Coombs G., Pearman J., Sharma A., Illingworth C., Crawford G., Easty D. Corneal biopsy with tissue micro-homogenisation for isolation of organisms in bacterial keratitis. Eye (Lond) 1999 Aug;13(Pt 4):545–549. doi: 10.1038/eye.1999.135. [DOI] [PubMed] [Google Scholar]
  6. Donnenfeld E. D., Schrier A., Perry H. D., Aulicino T., Gombert M. E., Snyder R. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology. 1994 May;101(5):902–905. doi: 10.1016/s0161-6420(13)31248-2. [DOI] [PubMed] [Google Scholar]
  7. Elena P. P., Jauch A. Ocular distribution of lomefloxacin 0.3% after a single instillation in the infected eye of pigmented rabbits. J Ocul Pharmacol Ther. 1997 Dec;13(6):551–558. doi: 10.1089/jop.1997.13.551. [DOI] [PubMed] [Google Scholar]
  8. Elner V. M., Strieter R. M., Pavilack M. A., Elner S. G., Remick D. G., Danforth J. M., Kunkel S. L. Human corneal interleukin-8. IL-1 and TNF-induced gene expression and secretion. Am J Pathol. 1991 Nov;139(5):977–988. [PMC free article] [PubMed] [Google Scholar]
  9. Euthanasia. N Engl J Med. 1989 Jul 13;321(2):119–120. doi: 10.1056/NEJM198907133210212. [DOI] [PubMed] [Google Scholar]
  10. Goldstein M. H., Kowalski R. P., Gordon Y. J. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999 Jul;106(7):1313–1318. [PubMed] [Google Scholar]
  11. HOGAN M. J., KIMURA S. J., THYGESON P. Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol. 1959 May;47(5 Pt 2):155–170. doi: 10.1016/s0002-9394(14)78239-x. [DOI] [PubMed] [Google Scholar]
  12. Hyndiuk R. A., Eiferman R. A., Caldwell D. R., Rosenwasser G. O., Santos C. I., Katz H. R., Badrinath S. S., Reddy M. K., Adenis J. P., Klauss V. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996 Nov;103(11):1854–1863. doi: 10.1016/s0161-6420(96)30416-8. [DOI] [PubMed] [Google Scholar]
  13. Insler M. S., Fish L. A., Silbernagel J., Hobden J. A., O'Callaghan R. J., Hill J. M. Successful treatment of methicillin-resistant Staphylococcus aureus Keratitis with topical ciprofloxacin. Ophthalmology. 1991 Nov;98(11):1690–1692. doi: 10.1016/s0161-6420(91)32067-0. [DOI] [PubMed] [Google Scholar]
  14. Limberg M. B. A review of bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol. 1991 Oct;112(4 Suppl):2S–9S. [PubMed] [Google Scholar]
  15. Lomholt J. A., Møller J. K., Ehlers N. Prolonged persistence on the ocular surface of fortified gentamicin ointment as compared to fortified gentamicin eye drops. Acta Ophthalmol Scand. 2000 Feb;78(1):34–36. doi: 10.1034/j.1600-0420.2000.078001034.x. [DOI] [PubMed] [Google Scholar]
  16. Matthews T. D., Frazer D. G., Minassian D. C., Radford C. F., Dart J. K. Risks of keratitis and patterns of use with disposable contact lenses. Arch Ophthalmol. 1992 Nov;110(11):1559–1562. doi: 10.1001/archopht.1992.01080230059020. [DOI] [PubMed] [Google Scholar]
  17. McDermott M. L., Tran T. D., Cowden J. W., Buggé C. J. Corneal stromal penetration of topical ciprofloxacin in humans. Ophthalmology. 1993 Feb;100(2):197–200. doi: 10.1016/s0161-6420(13)31672-8. [DOI] [PubMed] [Google Scholar]
  18. Miedziak A. I., Miller M. R., Rapuano C. J., Laibson P. R., Cohen E. J. Risk factors in microbial keratitis leading to penetrating keratoplasty. Ophthalmology. 1999 Jun;106(6):1166–1171. doi: 10.1016/S0161-6420(99)90250-6. [DOI] [PubMed] [Google Scholar]
  19. O'Brien T. P., Sawusch M. R., Dick J. D., Gottsch J. D. Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. Arch Ophthalmol. 1988 Oct;106(10):1444–1446. doi: 10.1001/archopht.1988.01060140608032. [DOI] [PubMed] [Google Scholar]
  20. Parks D. J., Abrams D. A., Sarfarazi F. A., Katz H. R. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol. 1993 Apr 15;115(4):471–477. doi: 10.1016/s0002-9394(14)74449-6. [DOI] [PubMed] [Google Scholar]
  21. Price F. W., Jr, Whitson W. E., Collins K. S., Gonzales J. S. Corneal tissue levels of topically applied ciprofloxacin. Cornea. 1995 Mar;14(2):152–156. [PubMed] [Google Scholar]
  22. Radford C. F., Minassian D. C., Dart J. K. Disposable contact lens use as a risk factor for microbial keratitis. Br J Ophthalmol. 1998 Nov;82(11):1272–1275. doi: 10.1136/bjo.82.11.1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Reidy J. J., Hobden J. A., Hill J. M., Forman K., O'Callaghan R. J. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Cornea. 1991 Jan;10(1):25–28. [PubMed] [Google Scholar]
  24. Schein O. D., Glynn R. J., Poggio E. C., Seddon J. M., Kenyon K. R. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med. 1989 Sep 21;321(12):773–778. doi: 10.1056/NEJM198909213211201. [DOI] [PubMed] [Google Scholar]
  25. Strieter R. M., Kunkel S. L., Elner V. M., Martonyi C. L., Koch A. E., Polverini P. J., Elner S. G. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol. 1992 Dec;141(6):1279–1284. [PMC free article] [PubMed] [Google Scholar]
  26. Vajpayee R. B., Dada T., Saxena R., Vajpayee M., Taylor H. R., Venkatesh P., Sharma N. Study of the first contact management profile of cases of infectious keratitis: a hospital-based study. Cornea. 2000 Jan;19(1):52–56. doi: 10.1097/00003226-200001000-00011. [DOI] [PubMed] [Google Scholar]
  27. Waxman E., Chechelnitsky M., Mannis M. J., Schwab I. R. Single culture media in infectious keratitis. Cornea. 1999 May;18(3):257–261. doi: 10.1097/00003226-199905000-00002. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES